ArticlePLoS pathogens2025
Ureaplasma-driven inhibition of the epithelial Na+ transport in fetal alveolar cells: A novel mechanism of Ureaplasma-mediated preterm lung disease.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Respiratory tract colonization with Ureaplasma species has been repeatedly associated with the development of acute and long-term pulmonary morbidity in preterm infants. However, despite strong evidence from observational studies and animal models, apart from inflammation, underlying mechanisms of Ureaplasma-driven lung disease, such as potential functional impairments, are mainly unknown. Knowledge of Ureaplasma-lung interaction and Ureaplasma virulence factors is scarce. The present investigation is the first to examine the influence of perinatal Ureaplasma infection on critical mechanisms of alveolar fluid clearance (AFC) in immature lung cells, which drive perinatal transition from fluid-filled lungs before birth to alveolar fluid absorption, enabling lung breathing. Disruption or impairment of these mechanisms could worsen respiratory distress in preterm infants and contribute to acute lung injury. Moreover, the present study addressed Ureaplasma-derived ammonia and the accompanying pH shift as potential virulence factors driving Ureaplasma-host interactions. Both have long been discussed as virulence factors, but remain unexamined, so far. We report that viable Ureaplasma isolates induced a 30-90% decrease in epithelial Na+ transport of primary rat fetal distal lung epithelial (FDLE) cells upon 24 hours of infection. Moreover, the decrease was linked to a significant inhibition of the epithelial Na+ channel (ENaC) and Na,K-ATPase activities, both mediating the essential AFC. It was observed that acute Ureaplasma infection induced phosphorylation of Erk1/2 - a well-known inhibitor of ENaC activity. Notably, exposure of FDLE cells to Ureaplasma-driven NH3 - in contrast to the hydrolysis-driven pH shift - fully mimicked Ureaplasma-driven effects and inhibited the epithelial Na+ transport. Co-incubation with the urease inhibitor flurofamide entirely restored Na+ transport in Ureaplasma-infected FDLE cells. Ureaplasma infection differentially modulated ENaC subunit and surfactant protein mRNA expression. In summary, the present study revealed a functional impairment of fetal pulmonary epithelial cells upon acute Ureaplasma infection and identified NH3 as a Ureaplasma virulence factor in this context. Co-incubation with flurofamide restored Na+ transport. This study describes a novel mechanism of Ureaplasma-driven early preterm lung disease, which might be of great significance for a deeper understanding of Ureaplasma-host interactions. Notably, the present findings offer a potential therapeutic role for urease inhibitors in Ureaplasma-colonized preterm infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.